BioLineRx (BLRX: Quote) announced that a Notice of Allowance has been issued by the United States Patent and Trademark Office, or USPTO, for a patent application claiming the composition of BL-1040, a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction. This patent, when issued, will be valid until August 2026.
The company noted that additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.
Dr. Kinneret Savitsky, BioLineRx's chief executive officer, said, "Currently approximately 1.5 million cases of myocardial infarction occur annually in the U.S. alone, many of which result in irreversible pathological cardiac remodeling. BL-1040 has demonstrated efficacy at preventing cardiac remodeling following an acute myocardial infarction in pre-clinical studies, giving new hope to patients around the world. In addition, we are pleased with the intensive efforts being made by Ikaria, our partner in this project, who is carrying out the CE Mark Registration Trial."
| || |
| To receive FREE breaking news email alerts for BioLineRx Ltd. and others in your portfolio|
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org